Boehringer Ingelheim and Microsoft expanded their AI ambitions for clinical development by working on “digital patient twins,” aiming to simulate disease progression and treatment response for trial design and controls. In parallel work, Boehringer is also moving further into China strategy. The company struck a cancer drug development licensing deal with Sino Biopharmaceutical, with Boehringer delivering $358 million upfront and up to $7 billion in additional payments tied to development and regulatory milestones, plus royalties. Together, the announcements underscore two related bets: faster evidence generation using AI and accelerated access to preclinical programs via regional partnerships.